Furthermore, although glucagon-like peptide-1 (GLP-1) receptor agonists provide a potent pharmaceutical intervention combatting obesity, the pronounced reductions in fat mass come at the expense of considerable losses in lean body mass [61]. Here, GLP1R is linked to obesity disorder.